On Demand Webinar: Accelerating the Development of a Virus-Like-Particle Vaccine against COVID-19

by Naomi Baer, Youssef Gaabouri and Jose M Galarza | July 15, 2022

Insights from a Global Collaboration Accelerating Vaccine Development with an Optimized VLP Platform

The COVID-19 pandemic further emphasized the need for collaboration in the development of urgently needed vaccines and therapeutics. In this webinar, we take you behind the scenes of our collaboration with TechnoVax and Innovative Biotech in which a scalable VLP vaccine platform was optimized or use in a production facility in Nigeria in response to the need for local production of SARS-CoV-2 vaccines. The flexibility and robustness of the platform will enable its rapid deployment to support the West African pandemic readiness program. Initial development of the VLP process began in late 2019 and by March 2020, was already adapted for production of a SARS-CoV-2 vaccine.

In this presentation we will explore:

About building a priceless collaborative network with integrated solutions
Virus-Like Particle Vaccines
Process Development Overview and Challenges
Pre-clinical Results and Next Steps

Register Now:

Webinar Accelerating the Development of a VLP Vaccine against Covid-19

Naomi Baer

Naomi Pintel Baer is a highly regarded Business Development Consultant at our company where she supports early-stage biopharma companies developing scalable upstream and downstream processes for advancing biologics into the clinic. She has more than 30 years of experience in the industry, including in the areas of research, process development, and QC biomonitoring. She began her career at a molecular biologist at Dupont. She graduated with a BS degree in biology from the University of the Sciences in Philadelphia, PA.

Youssef Gaabouri

Youssef Gaabouri joined the company in 2009 and has held various positions (Engineering, Biomanufacturing), focused on technologies for downstream processing, for monoclonal antibody and vaccine manufacturing. Before joining the company, he worked at Sanofi Pasteur as Project engineer for Vaccine manufacturing. Youssef holds an Engineering Degree from the Ecole Nationale Supérieure d’Agronomie et des Industries Alimentaires (ENSAIA) de Nancy-France with a focus on Biotechnology Processes.

Jose M Galarza

Jose M. Galarza, DVM, PhD, is the CEO and Founder of TechnoVax, Inc. and has more than 30 years of experience in the field of virology and vaccine development. Before founding TechnoVax, he was Principal Scientist and leader of the influenza subunit vaccine development program and member of the vaccine technology advisory board at Wyeth Pharmaceuticals. At Wyeth, he led the team that invented influenza Virus-Like Particle (VLP) vaccine technology. Dr. Galarza received a Doctorate in Veterinary Medicine and a Doctorate in Microbiology from the University of La Plata in Argentina.